RESUMO
Objective To evaluate the clinical effects ofHuoxue-Sanjie decoction combined with GEMOX chemotherapy regimen in the treatment of advanced pancreatic cancer with dampness-heat and stasis pattern.MethodsA total of 90 patients with advanced pancreatic cancer and TCM pattern of dampness-heat and stasis were enrolled from January 2012 to May 2014 in our hospital and randomly divided into control group (45 patients) and TCM group (45 patients). The control group was treated with GEMOX chemotherapy regimen used alone, while the TCM group was treated withHuoxue-Sanjie decoction assisted treatment based on control group. The clinical effects, quality improvement rate, immune function index and coagulation index before and after treatment and survival rate in 1 year after treatment and adverse events were compared between two groups.Results The total effective rate (73.33%vs. 66.67%,χ2=1.708,P=0.135) in TCM group was not significantly different from the control group. The survival rate in 1 year was (28.89%vs. 55.56%,χ2=10.406, P<0.01) in TCM group was significantly lower than that in control group. The adverse events (15.56% vs. 35.56%,χ2=8.728,P=0.002) in TCM group was significantly lower than that in control group. Compared with the control group, the CD3+ (65.20 ± 5.21 ratio/mlvs.62.94 ± 4.73 ratio/ml,t=2.106), CD4+ (36.86 ± 3.70 ratio/mlvs. 33.88 ± 3.04 ratio/ml,t=2.482), CD4+/CD8+(1.46 ± 0.30vs.1.36 ± 0.24,t=2.972) levels in TCM group increased significantly (P<0.05 orP<0.01). The PT (13.76 ± 1.70 svs. 14.73 ± 2.12 s,t=2.842), APTT (31.84 ± 2.53 svs. 36.97 ± 3.40 s,t=2.713), D-dimer (291.68 ± 25.15 mg/Lvs. 486.21 ± 44.32 mg/L,t=2.845), PLT (298.91×109/L ± 20.75×109/Lvs. 329.44×109/L ± 24.07×109/L,t=2.693) levels in TCM group significantly decreased (P<0.01).ConclusionHuoxue- Sanjie decoction combined with GEMOX chemotherapy regimen in the treatment of advanced pancreatic cancer for Shieryudu syndrome can improve the quality of life, prolong the survival time and helpreduce the risk of adverse events.
RESUMO
ObjectiveTo study the effect of self-designedFuzheng-Quxie-Jiedu decoction on transferring, relapse and liver quality of breast cancer patients after operation.Methods144 breast cancer patients after operation were divided into a study group and a control group. The control group was treated with CTF chemotherapy, and the study group was additionally treated with Chinese medicine. Both groups were treated for for 6 months. The 5-year recurrent rate and TCM syndrome scoring of the two groups were compared. The QOL was evaluated by SF-36 scale, and the related risk factors were tested by Logistic analysis. ResultsAfter treatment, the 5-year transferring recurrent rate of the study group lower than the control group (11.63%vs. 25.86%,χ2=4.892,P=4.892). The SF-36 scale body condition (72.11 ± 10.41 vs. 64.59 ± 9.83, t=3.252), social function (65.61 ± 12.54 vs. 58.94 ± 11.62,t=3.302), body role function (55.84 ± 10.65 vs. 47.46 ± 9.18,t=3.487), body pain (66.62 ± 12.53 vs. 60.68 ± 11.76,t=2.859), mental health (67.64 ± 11.35 vs. 62.65 ± 12.10,t=3.449), emotional role function (60.44 ± 9.20 vs. 55.04 ± 9.44),t=2.624), (69.77 ± 9.43 vs. 62.47 ± 10.12,t=3.557), and general health status (68.46 ± 10.25 vs. 62.45 ± 11.78,t=3.216) in the study group were all significantly increased comparing with the control group (P < 0.05). Results of logistic regression analysis showed that the transferring risk factors for recurrence were TNM staging (OR=1.984, 95%CI 1.510-2.607) and tumor size (OR=2.015, 95% CI2.015-2.847), the number of axillary lymph nodes (+) (OR=2.114, 95%CI 2.114-2.759), Chinese medicine adjuvant chemotherapy (OR=0.389, 95% CI0.235-0.644) and CD4/CD8 (OR=0.487, 95%CI 0.487-0.748).ConclusionSelf-designedFuzheng-Quxie-Jiedu decoction combined with standard chemotherapy can obviously reduce the recurrent rate of the postoperative patients with breast cancer, improve the quality of life and improve the clinical symptoms.
RESUMO
Objective To investigate the distribution of moderate to severe cancer pain and administrated dose of opioid drugs in order to provide the reference for the treatment of moderate and severe cancer pain.Methods Retrospective analyzed the clinical data of 146 patients with moderate to severe cancer pain.The information were recorded including opioid use dose,cancer pain incidence,age,gender,height,weight,body surface area and type of tumor.Results There were no significant difference among patients with opioids drug administration in terms of gender,average daily oral dose(x2 =0.473,Z =-0.185,P ＞ 0.05).Meanwhile cancer incidence rate was same in different age groups (x2 =2.280,P =0.684).The average daily opioid dose in patients with over 80 year old was the lowest among other age groups (Z =-2.745,-1.986,-2.141,-2.162;P ＜0.05).Cancer pain incidence in patients with hepatobiliary pancreatic tumors were 67.50％ (27/40),highest than other different types cancer including metastatic tumor(62.50％ (10/16)),urinary tumor (61.54％ (8/13)),lung cancer (52.63％ (50/95)),breast cancer and gynecological tumor (50.00％ (17/34)),gastrointestinal tumor(41.94％ (26/62)),other tumors 38.46％ (5/13) and head and neck tumor(25.00％ (3/12)),the difference was statistically significant (x2 =23.672,P ＜ 0.05).The average day oral morphine dose of different types tumor were listed as followed from high to low in the order:160 (80,200) mg of metastatic tumors,120 (60,160) mg of breast and gynecological tumor,100 (40,125) mg of lung cancer,90(45,115) mg of urinary tract tumors,80(60,160) mg of other tumors,70(50,90) mg of hepatobiliary pancreatic tumor,60 (40,80) mg of gastrointestinal tumor,55 (40,70) mg of head and neck tumor.There were significant differences in terms of among oral morphine dose per day of different type tumors (H=14.280,P ＜0.05).No correlation was found between pain patients with height,body mass,body surface area and average daily dose of morphine (r =-0.045,-0.042,-0.046 ; P ＜ 0.05).Conclusion No significant differences were found in terms of moderate to severe cancer pain among different type tumors at different and age groups.While there is significant difference in term of cancer pain incidence among different tumor types.The average daily amount of morphine in patients with cancer pain is not related to gender,height,body mass and body surface area.The average amount of morphine of patients with age over 80 years old is significantly lower than that of the other age groups,and the average amount of morphine t is related to cancer type.